Table 2 Clinical benefit and progression-free survival: multivariate analyses in patients with molecular alterations

Risk Factor (vs. other)

OR

95% CI

p

PI3K/AKT/mTOR alterations

.73

.53–1.02

.06

Liver metastases

.54

.39–.76

< .001

LDH > ULN

.61

.43–.86

.004

Performance status > 1

.50

.24–1.02

.06

Albumin < ULN

.68

.37–1.25

.21

 Non-matched therapy

.67

.49–.90

.01

 PI3K/AKT/mTOR alterations

.67

.48–.94

.02

 Liver metastases

.55

.39–.77

< .001

 LDH > ULN

.63

.45–.89

.01

 Performance status > 1

.51

.25–1.05

.07

 Albumin < ULN

.69

.97–1.27

.23

Risk Factor (vs. other)

HR

95% CI

p

PI3K/AKT/mTOR alterations

1.11

.98–1.27

.09

Liver metastases

1.45

1.27–1.64

< .001

LDH > ULN

1.50

1.31–1.70

< .001

Performance status > 1

1.57

1.24–1.99

< .001

Albumin < ULN

1.35

1.09–1.67

.01

Platelets > ULN

1.14

.85–1.53

.39

Age ≥ 60 years

.97

.86–1.09

.57

 Non-matched therapy

1.39

1.23–1.58

< .001

 PI3K/AKT/mTOR alterations

1.16

1.02–1.32

.02

 Liver metastases

1.43

1.26–1.62

< .001

 LDH > ULN

1.44

1.26–1.64

< .001

 Performance status > 1

1.54

1.22–1.95

< .001

 Albumin < ULN

1.31

1.06–1.62

.01

 Platelet count > ULN

1.09

.81–1.46

.59

 Age ≥ 60 years

.95

.84–1.07

.37